Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp utcomes after implantation of pulsatile left ventricular assist device (LVAD) appear to have been critically dependent on postoperative right ventricular (RV) function. 1-3 Recent innovations of LVAD pumps have dramatically decreased device-related complications and improved overall prognosis, 4-7 but postoperative RV failure is still a serious concern even in the era of continuous flow pumps. 7,8
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RV stroke work index (RVSWI) 3,11,12 and the ratio of central venous pressure to pulmonary capillary wedge pressure (CVP/ PCWP) 8 have been widely used. These indices need an invasive measurement of hemodynamics in severely ill patients, and instead some investigators claim that combinations of preoperative parameters, which are able to be non-invasively obtained, well predict postoperative RV failure. 11- 15 We maintain, however, that preoperative risk stratification for the necessity of BiVAD remains to be elucidated, and that there have been very few reports from Japan. 16 The aim of this study was to identify preoperative risk factors for the requirement of BiVAD therapy and to create a novel scoring system (Todai RV failure score: TRV score) for predicting BiVAD therapy.
Methods

Subjects
We retrospectively analyzed 83 consecutive patients with endstage heart failure who were treated with LVAD between November 2002 and December 2011 and followed at the University of Tokyo Hospital. Every patient was considered as eligible for transplantation at least at the time of LVAD implantation. We excluded 4 patients whose data were insufficient to analyze, and finally we could analyze 79 patients according to endpoint (death, explantation of VADs with recovery of native heart, or heart transplantation) or the end of follow-up on VAD support. Patients were all treated with standard medical therapy before LVAD implantation and, if indicated, cardiac resynchronization therapy. LVAD was usually implanted due to cardiogenic shock or progressive decline of end-organ function due to low cardiac output in spite of i.v. inotropic agents. Percutaneous cardiopulmonary support (PCPS), intra-aortic balloon pumping, and/or continuous hemodiafiltration (CHDF) were introduced if necessary.
Those who required RVAD in addition to LVAD were assigned to the BiVAD group. In this study, RVAD therapy included an ECMO system and/or NIPRO-VAD inserted in the RV or right atrium (RA). Written informed consent was obtained before VAD implantation. The study protocol was approved by the Ethics Committee of Graduate School of Medicine, University of Tokyo (application number 779 [1] ).
Hemodynamic data of patients with fulminant myocarditis were available only before PCPS insertion if any, but these data might not reflect preoperative status considering the rapid nature of the clinical course. Therefore, we excluded 3 patients with fulminant myocarditis from the main analysis. As a consequence, we analyzed data from 76 patients.
Hemodynamic measurement was performed in 55 patients who underwent right heart catheterization preoperatively. Analyzed data included cardiac index (CI), mean RA pressure (RAP), PCWP, mean pulmonary artery pressure (mPAP), systolic pulmonary artery pressure, diastolic pulmonary artery pressure (dPAP), CVP, transpulmonary pressure gradient (TPG): mPAP-PCWP, CVP/PCWP ratio, and RVSWI. RVSWI was calculated using the following formula: (CI/heart rate) × (mPAP-RAP) × 13.6. 3 In some cases we used dPAP and mean CVP as substitutes for PCWP and RAP, respectively. In patients who were treated with PCPS before LVAD implantation, we used data of right heart catheterization before PCPS insertion. RV failure risk score (RVFS) from the University of Michigan was also calculated based on the formula provided previously. 13 
Statistical Analysis
We used PASW Statistics 18 (SPSS) and JMP version 9.0 (SAS Institute) for statistical analysis. Continuous variables are expressed as mean ± SD and were compared using unpaired ttest. Categorical variables are expressed as percentages and were compared using chi-square test. Kaplan-Meier analysis was used to estimate survival. Survival between each group was compared by log-rank test. Plasma level of B-type natriuretic peptide (BNP) was changed into logarithmic data to fit a normal distribution when compared between 2 groups. Univariate and multivariate analysis with a logistic regression model were performed to calculate adjusted odds ratio (OR) and 95% confidence intervals to assess preoperative risk factors for the requirement of BiVAD therapy. Categorical variables that had a tendency (P<0.10) to associate with BiVAD requirement on univariate analysis were used in multivariate analysis with a stepwise method. To select variables for multivariate analysis, multicollinearity was assessed using Pearson's product-moment correlation coefficients (Table S1 ). Receiver operating characteristic (ROC) analysis for the requirement of BiVAD therapy was carried out on TRV score, 1/RVSWI, CVP/PCWP ratio and RVFS. Cut-offs of continuous variables were determined using JMP version 9.0. Probability was 2-tailed with P<0.05 regarded as statistically significant. 
Results
Baseline Patient Characteristics
The baseline characteristics of the total 79 patients are listed in Table 1 . There were 9 BiVAD patients (11.4%), and all BiVAD patients received NIPRO-VAD in LV. Among the 9 patients with BiVAD, 6 patients received ECMO as well as RVAD. The remaining 3 patients had implantation of NIPRO-VAD in RV. Table 2 summarizes comparison of baseline characteristics and hemodynamic parameters between the LVAD and BiVAD patients. The BiVAD group was characterized by smaller body surface area (BSA), shorter period of LVAD support, smaller left ventricular diastolic diameter (LVDd), lower C-reactive protein and higher logarithmic BNP. RVFS was not significantly different between LVAD and BiVAD groups. With regard to hemodynamic parameters for right heart catheterization, CVP/PCWP ratio was significantly higher in the BiVAD group. Lower RVSWI was also significantly associated with BiVAD group.
Comparison of Survival Between LVAD Patients and BiVAD Patients
As shown in Figure 1 , the survival rate of BiVAD patients was markedly lower than that of LVAD patients (P<0.001, logrank test). Of all 6 deceased in the BiVAD group, 4 patients (66.7%) died due to multiple organ failure within the first 3 months. Another 2 patients died of sepsis and device failure.
Univariate and Multivariate Preoperative Risk Factors
Univariate analysis of predictors of BiVAD requirement from among baseline characteristics and biochemical indices is given in Table 3 . Age <23 years, BSA <1.40 m 2 , preoperative use of CHDF, LVDd <62 mm, and higher plasma BNP were significantly associated with BiVAD requirement. Serum total bili- rubin >4.8 mg/dl and plasma BNP >1,200 pg/ml had a tendency to associate with BiVAD requirement. Multivariate analysis showed that LVDd <62 mm was an independent risk factor for BiVAD implantation. Table 3 also lists univariate analysis of preoperative hemodynamic parameters. We found that CVP/PCWP >0.5 and RVSWI <4.0 had a significant association with BiVAD requirement. Because of the close correlation among PCWP, CVP/PCWP ratio and RVSWI (Table S1) , multivariate analysis of these hemodynamic parameters was avoided.
New Score for BiVAD Requirement: TRV Score We selected 4 risk factors from among baseline characteristics and biochemical indices on the basis of univariate and multivariate analysis. We included CVP/PCWP ratio as well. Based on the ORs from univariate analysis, a weighted coefficient was assigned to each of them in order to construct the new TRV score ( Table 4) . To compare the predictability for BiVAD requirement among TRV score, CVP/PCWP ratio, 1/RVSWI Tables 1,2 . New Scoring for Stratification of BiVAD Requirement and RVFS, we performed ROC analysis ( Figure 2 ). As shown in Table 4 , the area under the curve of TRV score was larger than that of CVP/PCWP ratio, 1/RVSWI and RVFS. From this ROC analysis, we determined a cut-off for TRV score of 20 points (specificity/sensitivity 0.800/0.800; Figure 2 ). Table 4 also lists the results of univariate analysis of TRV score for BiVAD requirement. TRV score >20 points indicated a significantly higher risk of BiVAD requirement.
Discussion
Among the 79 LVAD patients, 11.4% of them required BiVAD therapy, and the survival rate of BiVAD patients was extremely poor. Univariate and multivariate analysis showed that younger age, smaller BSA, preoperative use of CHDF, higher plasma BNP, smaller LV cavity, higher CVP/PCWP ratio and lower RVSWI were significantly associated with BiVAD requirement. We constructed a new scoring system (TRV score) composed of a combination of preoperative risk factors, BSA (≤1.40 m 2 ), CHDF (+), BNP (≥1,200 pg/ml), LVDd (≤62 mm) and CVP/PCWP ratio (≥0.5). ROC analysis showed that TRV score was the best discriminative indicator for BiVAD requirement among RVSWI, CVP/PCWP ratio and RVFS.
According to the present data, BiVAD patients comprised 11.4% of all VAD patients, and the prevalence was similar to the number reported from INTERMACS. 9 The prognosis of these BiVAD patients was extremely poor as compared with LVAD patients. Deaths occurred in the first 3 months after BiVAD therapy, and the main cause of death was multiple organ failure. Considering this, it appears that preoperative end-organ dysfunction was too bad to be restored in many of the BiVAD patients. According to the INTERMACS registry, there was a 2-4-fold higher adverse event rate of bleeding and infection in the BiVAD group than in the LVAD group. 9 Sustained liver dysfunction may be a predisposing factor toward fatal bleeding or infection in the postoperative period.
A couple of studies have reported that smaller BSA as well as younger age were often associated with BiVAD requirement. 9, 11 Of the present 9 patients in the BiVAD group, 3 patients were in their teens, 2 of whom had dilated cardiomyopathy and 1 had large myocardial infarction resulting from Kawasaki disease. Cardiomyopathy of younger onset may have a strong genetic cause that also affects RV equally to LV. Another possibility is that RV in youth may be more susceptible to ischemic damage. Further studies are needed to clarify this point.
We found that smaller LV cavity was significantly associated with BiVAD requirement. As shown in the present data, PCWP was lower in BiVAD patients. Severe RV dysfunction decreases preload for LV, which well explains lower PCWP and smaller LV cavity. According to the statistical analysis, BSA and LVDd were not significantly correlated (Table S1) . Therefore, smaller LVDd may not necessarily be a consequence of smaller stature. End-organ dysfunction including that of liver or kidney was not only the determinant of prognosis but the predictor for BiVAD requirement. Univariate analysis showed that preoperative CHDF use was significantly associated with higher risk of BiVAD implantation. The importance of preoperative end-organ function has been reported in a number of papers, 1-3,8,9,11-13 but in contrast such a combination of parameters as RVFS, 13 which can be measured non-invasively, failed to show good predictability in the present patients. This led us to include preoperative hemodynamic data into the TRV score system.
The CVP/PCWP ratio 8 or RVSWI 3 has been widely used as a marker for preoperative RV dysfunction. We also showed that these 2 parameters predicted BiVAD requirement well in the present study. But we had 1 patient for whom it was difficult to assess preoperative RV function accurately by RVSWI. Table 5 lists the details of this case, involving a patient with dilated cardiomyopathy in whom RVSWI was low even though there was no RV failure. RVSWI is largely dependent on the level of PAP. In this case, low RVSWI may be attributable to the relaxation of pulmonary artery by 100% oxygen. From this experience, we considered that combination evaluation including CVP/PCWP ratio for BiVAD requirement is necessary. TRV score, in contrast, was consistently 7 in the first and second hemodynamic measurement.
The idea on which construction of TRV score was based, is that preoperative RV function primarily determines the need for RVAD. The present analysis, however, was dependent on the subject group, which mostly consisted of patients with an extracorporeal pulsatile pump. Recently, Kormos et al reported that rate of RVAD requirement was low (6%) in patients with HeartMate II for LV. 8 Some may argue that lower flow of NIPRO-VAD may have contributed to the higher incidence of RVAD requirement in the present study (12%), but let us note that implantable pulsatile VADs such as HeartMate XVE had a similar BiVAD frequency, 9 regardless of the potential of flow as high as HeartMate II. Therefore, the superiority of HeartMate II is not a matter of flow quantity, but is largely explained by the recent trend of earlier LVAD implantation in less-sick patients. Less-sick patients may have less severe RV involvement, if any. Furthermore, less-sick patients have less impairment of liver dysfunction, which is accompanied by lower risk for perioperative bleeding. Large amount of blood transfusion during the perioperative period often exacerbates RV dysfunction even though RV dysfunction is latent preoperatively. Now, in the era of the continuous flow pump in Japan, 5 our new scoring system can contribute to earlier decisionmaking for LVAD implantation before RV dysfunction and/or end-organ damages become irreversible.
Such earlier implantation of continuous flow LVAD may decrease the necessity of RVAD, but a certain number of patients will still require BiVAD because of intrinsic severe RV dysfunction. The TRV score can pick up those patients preoperatively, but even if we know that RV function is very bad, is there anything that can be done for the patient? It seems that all that can be done right now is to implant the best available LVAD and keep our fingers crossed. What else can be prepared in advance? There was a report that patients who were treated with planned BiVAD had better survival compared with patients in whom failed LVAD therapy necessitated BiVAD later. 17 In contrast, Cleveland et al analyzed whether durable LVAD/durable RVAD for BiVAD had superiority of prognosis over durable LVAD/temporary RVAD. Durable LVAD/ durable RVAD represents a deliberate or planned strategy for BiVAD in most cases, whereas durable LVAD/temporary RVAD may be a result of failed LVAD in many cases, that is, unexpected BiVAD therapy. But they did not find any differences in survival between these 2 groups. 9 The 2 findings described here contradict each other. The discrepancy should be clarified in future, but may be explained by the fact that durable RVADs were all pulsatile flow pumps even in the most recent era. As has been well-established in LVAD, pulsatile flow pumps are associated with lower survival rate and poorer quality of life than continuous flow pumps. 7 In Japan, only an extracorporeal pulsatile pump has been available for RVAD, therefore it has not been possible to plan BiVAD therapy in advance. Planned BiVAD becomes a real option only when we are able to use continuous flow implantable pumps as RVADs. Recently, BiVAD systems with 2 continuous flow pumps have been reported, 18-20 and planned BiVAD therapy with implantable VADs may now be possible. In order to stratify patients suitable for planned BiVAD therapy, and as a result to successfully bridge them to transplantation, our new scoring system can be an efficient tool.
Several limitations of this study must be acknowledged. This study was conducted in a single center and therefore was limited in the number of enrolled patients. All data were analyzed in a retrospective manner. In addition, >75% of patients received an extracorporeal pulsatile LVAD in the present study, and all patients with BiVAD were implanted with extracorporeal pulsatile pumps in the LV and RV. TRV score has been mainly constructed on the data from 5 BiVAD patients in whom we were able to analyze hemodynamic results, and the small number of data limit statistical power. Finally, the TRV score should be tested in a prospective manner as to whether it works in the era of continuous flow pumps for LVAD.
In conclusion, we have described a new scoring system that consists of CVP/PCWP ratio (≥0.5), BSA (≤1.4 m 2 ), preoperative use of CHDF, BNP (≥1,200 pg/ml) and LVDd (≤62 mm), and which could be an effective tool for preoperative stratification for BiVAD requirement.
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